1. Home
  2. MBBC vs SCYX Comparison

MBBC vs SCYX Comparison

Compare MBBC & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MBBC
  • SCYX
  • Stock Information
  • Founded
  • MBBC 1902
  • SCYX 1999
  • Country
  • MBBC United States
  • SCYX United States
  • Employees
  • MBBC N/A
  • SCYX N/A
  • Industry
  • MBBC Banks
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MBBC Finance
  • SCYX Health Care
  • Exchange
  • MBBC Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • MBBC 29.3M
  • SCYX 28.5M
  • IPO Year
  • MBBC N/A
  • SCYX 2014
  • Fundamental
  • Price
  • MBBC $10.05
  • SCYX $0.74
  • Analyst Decision
  • MBBC
  • SCYX
  • Analyst Count
  • MBBC 0
  • SCYX 0
  • Target Price
  • MBBC N/A
  • SCYX N/A
  • AVG Volume (30 Days)
  • MBBC 10.3K
  • SCYX 188.8K
  • Earning Date
  • MBBC 08-22-2025
  • SCYX 08-07-2025
  • Dividend Yield
  • MBBC N/A
  • SCYX N/A
  • EPS Growth
  • MBBC 103.56
  • SCYX N/A
  • EPS
  • MBBC 0.22
  • SCYX N/A
  • Revenue
  • MBBC $6,591,743.00
  • SCYX $2,630,000.00
  • Revenue This Year
  • MBBC N/A
  • SCYX $410.22
  • Revenue Next Year
  • MBBC N/A
  • SCYX $248.83
  • P/E Ratio
  • MBBC $45.63
  • SCYX N/A
  • Revenue Growth
  • MBBC N/A
  • SCYX N/A
  • 52 Week Low
  • MBBC $6.38
  • SCYX $0.66
  • 52 Week High
  • MBBC $12.00
  • SCYX $2.28
  • Technical
  • Relative Strength Index (RSI)
  • MBBC N/A
  • SCYX 46.93
  • Support Level
  • MBBC N/A
  • SCYX $0.67
  • Resistance Level
  • MBBC N/A
  • SCYX $0.83
  • Average True Range (ATR)
  • MBBC 0.00
  • SCYX 0.05
  • MACD
  • MBBC 0.00
  • SCYX 0.01
  • Stochastic Oscillator
  • MBBC 0.00
  • SCYX 47.06

About MBBC Marathon Bancorp Inc. Common Stock

Marathon Bancorp Inc is a Wisconsin-chartered savings bank. It is a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the Company's revenues come from interest income on loans and debt securities.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: